BIO101 for obesity and semaglutide-associated muscle preservation
undiscloseddrug program · high · Wed Jul 01 2026 00:00:00 GMT+0000 (Coordinated Universal Time)
Improve or preserve muscle strength, physical function, lean body mass, and quality of life in adults with obesity or overweight with sequelae who are treated with semaglutide for weight loss.
Clinical trial of oral BIO101 or placebo for 21 weeks alongside semaglutide, caloric restriction, and clinic assessments; primary muscle-strength measure is knee extension strength using isokinetic dynamometry.
ClinicalTrials.gov record supplied for trial NCT07411378.
BIO101 for prevention of respiratory deterioration in COVID-19
phase 3drug program · medium · Wed Jan 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Prevent respiratory deterioration in patients with SARS-CoV-2 pneumonia by activating the Mas receptor through the protective arm of the renin-angiotensin system.
Global multicenter double-blind placebo-controlled adaptive Phase 2-3 study of BIO101, with Phase 2 proof-of-concept and Phase 3 pivotal components after 28 days of dosing.
ClinicalTrials.gov record and 2025 review discussing randomized trials of renin-angiotensin system modulators in COVID-19.
Supplied review states RAS-modulator COVID-19 trials had mixed outcomes, mostly neutral, with some reaching primary endpoints; no BIO101-specific efficacy result is provided in the supplied material.
BIO101 for sarcopenia
phase 2drug program · high · Wed Jan 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Treat sarcopenia in older adults at risk of mobility disability by improving muscle function and physical performance.
Randomized double-blind placebo-controlled Phase 2b trial of oral BIO101 175 mg bid or 350 mg bid versus placebo, measuring gait speed by 400-meter walk test and other physical performance endpoints.
Phase 2b SARA-INT results published in 2025.
BIO101 350 mg bid showed a 0.07 m/s gait-speed improvement versus placebo in the full analysis set and 0.09 m/s in the per-protocol population (p=0.008), with good safety profile; COVID-19 caused substantial missing endpoint data.
BIO101 for spinal muscular atrophy
preclinicaldrug program · high · Wed Jan 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Improve muscle performance in spinal muscular atrophy as a SMN-independent therapy, either alone or combined with SMN-based therapy.
BIO101 treatment in severe and mild Taiwanese SMA mouse models and SMA patient-derived myoblasts, including combination testing with ASO-10-27/nusinersen-like antisense therapy.
Preclinical results published in Journal of Cachexia, Sarcopenia and Muscle in 2025.
BIO101 protected motor neurons, limited muscular atrophy, accelerated muscle fiber and neuromuscular junction maturation, improved motor function in SMA mice, improved patient-derived myoblast differentiation, and enhanced fatigue resistance when combined with ASO-10-27.
SARA-OBS sarcopenia and sarcopenic obesity observational program
phase 2research program · medium · Wed Jan 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Characterize sarcopenia and sarcopenic obesity and their consequences on physical function over time in community-dwelling adults aged 65 years and older at risk of mobility disability.
Single-arm observational multicenter trial with mobility testing, DXA body-composition analysis, 6-minute walk distance, 400-meter walk test, and patient-reported outcomes at baseline and six months.
SARA-OBS results published in 2025 and ClinicalTrials.gov record available.
The supplied abstract describes characterization of sarcopenia and sarcopenic obesity in older adults at risk of mobility disability; detailed outcome values are not included in the supplied material.
Biophytis longevity research platform
exploratoryplatform · medium
Use multiple technologies accelerated by AI to support longevity therapeutic discovery and development.
Longevity research platform using AI-enabled technologies; specific assays, models, or platform outputs are not detailed in the supplied material.
Company site analysis identifies the platform as part of Biophytis strategy.
